| Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer S Modi, W Jacot, T Yamashita, J Sohn, M Vidal, E Tokunaga, J Tsurutani, ... New England Journal of Medicine 387 (1), 9-20, 2022 | 1315 | 2022 |
| Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355 … J Cortes, DW Cescon, HS Rugo, Z Nowecki, SA Im, MM Yusof, C Gallardo, ... The Lancet 396 (10265), 1817-1828, 2020 | 1288 | 2020 |
| Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally … D Miles, J Gligorov, F André, D Cameron, A Schneeweiss, C Barrios, B Xu, ... Annals of Oncology 32 (8), 994-1004, 2021 | 472 | 2021 |
| Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors N Niikura, J Liu, N Hayashi, EA Mittendorf, Y Gong, SL Palla, Y Tokuda, ... Journal of Clinical Oncology 30 (6), 593-599, 2012 | 469 | 2012 |
| Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21 755 patients from the Japanese breast cancer registry N Niikura, A Tomotaki, H Miyata, T Iwamoto, M Kawai, K Anan, N Hayashi, ... Annals of oncology 27 (3), 480-487, 2016 | 169 | 2016 |
| Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis N Niikura, N Hayashi, N Masuda, S Takashima, R Nakamura, ... Breast cancer research and treatment 147, 103-112, 2014 | 169 | 2014 |
| Comparison of tumor‐infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients R Ogiya, N Niikura, N Kumaki, G Bianchini, S Kitano, T Iwamoto, ... Cancer science 107 (12), 1730-1735, 2016 | 142 | 2016 |
| FDG‐PET/CT compared with conventional imaging in the detection of distant metastases of primary breast cancer N Niikura, CM Costelloe, JE Madewell, N Hayashi, TK Yu, J Liu, SL Palla, ... The oncologist 16 (8), 1111-1119, 2011 | 121 | 2011 |
| Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers M Itoh, T Iwamoto, J Matsuoka, T Nogami, T Motoki, T Shien, N Taira, ... Breast cancer research and treatment 143, 403-409, 2014 | 108 | 2014 |
| Distinct gene expression profiles between primary breast cancers and brain metastases from pair-matched samples T Iwamoto, N Niikura, R Ogiya, H Yasojima, K Watanabe, C Kanbayashi, ... Scientific reports 9 (1), 13343, 2019 | 97 | 2019 |
| Comparison of immune microenvironments between primary tumors and brain metastases in patients with breast cancer R Ogiya, N Niikura, N Kumaki, H Yasojima, T Iwasa, C Kanbayashi, ... Oncotarget 8 (61), 103671, 2017 | 85 | 2017 |
| Treatment outcome and prognostic factors for patients with bone‐only metastases of breast cancer: a single‐institution retrospective analysis N Niikura, J Liu, N Hayashi, SL Palla, Y Tokuda, GN Hortobagyi, NT Ueno, ... The Oncologist 16 (2), 155-164, 2011 | 79 | 2011 |
| Young adult breast cancer patients have a poor prognosis independent of prognostic clinicopathological factors: a study from the Japanese Breast Cancer Registry A Kataoka, T Iwamoto, E Tokunaga, A Tomotaki, H Kumamaru, H Miyata, ... Breast cancer research and treatment 160, 163-172, 2016 | 74 | 2016 |
| Prognostic significance of the Ki67 scoring categories in breast cancer subgroups N Niikura, S Masuda, N Kumaki, T Xiaoyan, M Terada, M Terao, ... Clinical breast cancer 14 (5), 323-329. e3, 2014 | 70 | 2014 |
| Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer T Ochi, G Bianchini, M Ando, F Nozaki, D Kobayashi, C Criscitiello, ... European Journal of Cancer 118, 41-48, 2019 | 67 | 2019 |
| Atezolizumab with neoadjuvant anti–human epidermal growth factor receptor 2 therapy and chemotherapy in human epidermal growth factor receptor 2–positive early breast cancer … J Huober, CH Barrios, N Niikura, M Jarząb, YC Chang, ... Journal of Clinical Oncology 40 (25), 2946-2956, 2022 | 66 | 2022 |
| Pretreatment staging positron emission tomography/computed tomography in patients with inflammatory breast cancer influences radiation treatment field designs GV Walker, N Niikura, W Yang, E Rohren, V Valero, WA Woodward, ... International Journal of Radiation Oncology* Biology* Physics 83 (5), 1381-1386, 2012 | 58 | 2012 |
| Immunohistochemical K i67 labeling index has similar proliferation predictive power to various gene signatures in breast cancer N Niikura, T Iwamoto, S Masuda, N Kumaki, T Xiaoyan, M Shirane, K Mori, ... Cancer science 103 (8), 1508-1512, 2012 | 56 | 2012 |
| Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of … S Modi, W Jacot, T Yamashita, J Sohn, M Vidal, E Tokunaga, J Tsurutani, ... Journal of Clinical Oncology 40 (17_suppl), LBA3-LBA3, 2022 | 54 | 2022 |
| Body mass index and survival after diagnosis of invasive breast cancer: a study based on the Japanese National Clinical Database—Breast Cancer Registry M Kawai, A Tomotaki, H Miyata, T Iwamoto, N Niikura, K Anan, N Hayashi, ... Cancer medicine 5 (6), 1328-1340, 2016 | 54 | 2016 |
